Researchers in the U.K. have uncovered key genetic changes driving intervertebral disc degeneration, a leading cause of back pain. By studying gene activity and spinal hardening in zebrafish, scientists identified potential drug targets—including an existing osteoporosis medication—that could offer alternatives to surgery for millions of sufferers.
Genetic Faults and Spinal Hardening in Zebrafish Models
Back pain affects most people at some point in their lives, driven largely by the gradual breakdown of the spinal discs that cushion the vertebrae. For generations, surgery has remained the only long-term option for advanced cases.
To investigate how genetic faults initiate this breakdown, scientists from the Universities of Edinburgh and Bristol studied zebrafish bred to lack a working copy of a gene linked to collagen IX—a protein essential for holding spinal disc structural fibers together. As these fish aged, their spines developed abnormalities resembling human disc disease, characterized by spinal bone fusion and abnormal mineral deposits within the vertebrae.
“For decades, surgery has been the only real answer for disc disease. By understanding the biology that drives the spine to harden, our zebrafish studies point to several ways of slowing it down, including a drug already used safely in patients.”
Erika Kague, University of Edinburgh Institute of Genetics and Cancer
Researchers observed that this tissue hardening was preceded by a distinct breakdown in a supportive scaffold layer within the developing spine, occurring well before any mineral accumulation began. Gene expression analysis revealed widespread disruptions in lipid handling, phosphate processing, vitamin A signaling, and a growth-control pathway known as mTOR.
Potential Drug Targets and Dietary Interventions
By identifying the biological pathways responsible for mineral buildup, the research team was able to test interventions aimed at reducing spinal damage. Administering bisphosphonate—a bone-protecting drug already used for osteoporosis—effectively blocked the mineral accumulation in the zebrafish models. Additionally, simple food intake restrictions and pharmacological agents that dampen fat metabolism successfully reduced spinal fusions.
These experimental results point toward phosphate handling and fat metabolism as promising avenues for developing future therapeutic drugs. While further investigation is required before clinical trials can begin, researchers emphasize the value of zebrafish as a tool for screening prospective treatments for a condition that has impacted generations without targeted medical interventions.
“There’s more work to do, but for a condition that’s affected people for generations without a treatment in sight, this is super exciting.”
Erika Kague, University of Edinburgh Institute of Genetics and Cancer
The findings carry significant public health implications in regions like the United Kingdom, where millions live with debilitating spinal conditions.
“For the 9.5 million people across the U.K. living with back pain, this research brings fresh hope that potential new therapeutic approaches are on the horizon.”
Caroline Aylott, Arthritis UK
Broad Genomic Architecture and the Biopsychosocial Model
The cellular investigations align with broader epidemiological findings concerning the complex heritability of back pain. A genome-wide association study examining data from 509,070 individuals across the UK Biobank and CHARGE consortium cohorts revealed that back pain shares genetic architecture with both structural anomalies and psychological risk factors. Researchers identified three back pain-associated loci, including a novel region implicating the SPOCK2 and CHST3 genes.
This genomic mapping reinforces the biopsychosocial model of back pain. Statistical analyses demonstrate distinct molecular axes: one tied to anatomical and structural factors such as intervertebral disk problems, and another linked to psychological elements like pain perception, neuroticism, depression symptoms, sleep disturbance, and smoking.
Complementary laboratory efforts are also transforming how scientists study the structural mechanics of spinal degeneration. Researchers at the University of Manchester have successfully pioneered a 3D bioprinting technique to replicate the complex architecture of human spinal discs using cell-friendly hydrogels made from collagen and seaweed-derived alginate.
Published in Manchester, the Manchester study demonstrates that local tissue stiffness and oxygen levels directly govern how disc cells produce vital biological materials like collagen and hyaluronic acid. These sophisticated tissue models allow researchers to analyze cell behavior under precise physiological conditions without relying exclusively on animal subjects, paving the way for future regenerative therapies incorporating stem cells.
